{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:29:04Z","timestamp":1793035744433,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":267,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by &amp;gt;10-fold. The objective of this study was to examine the public health impact of ADPKD in the European Union (EU) by estimating minimum prevalence (point prevalence of known cases) and screening prevalence (minimum prevalence plus cases expected after population-based screening).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of the epidemiology literature from January 1980 to February 2015 identified population-based studies that met criteria for methodological quality. These examined large German and British populations, providing direct estimates of minimum prevalence and screening prevalence. In a second approach, patients from the 2012 European Renal Association\u2012European Dialysis and Transplant Association (ERA\u2013EDTA) Registry and literature-based inflation factors that adjust for disease severity and screening yield were used to estimate prevalence across 19 EU countries (N = 407 million).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Population-based studies yielded minimum prevalences of 2.41 and 3.89\/10 000, respectively, and corresponding estimates of screening prevalences of 3.3 and 4.6\/10 000. A close correspondence existed between estimates in countries where both direct and registry-derived methods were compared, which supports the validity of the registry-based approach. Using the registry-derived method, the minimum prevalence was 3.29\/10 000 (95% confidence interval 3.27\u20133.30), and if ADPKD screening was implemented in all countries, the expected prevalence was 3.96\/10 000 (3.94\u20133.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ERA\u2013EDTA-based prevalence estimates and application of a uniform definition of prevalence to population-based studies consistently indicate that the ADPKD point prevalence is &amp;lt;5\/10 000, the threshold for rare disease in the EU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfw240","type":"journal-article","created":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T17:13:18Z","timestamp":1466529198000},"page":"1356-1363","source":"Crossref","is-referenced-by-count":126,"title":["Prevalence of autosomal dominant polycystic kidney disease in the European Union"],"prefix":"10.1093","volume":"32","author":[{"given":"Cynthia J.","family":"Willey","sequence":"first","affiliation":[{"name":"1College of Pharmacy, University of Rhode Island, Kingston, RI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime D.","family":"Blais","sequence":"additional","affiliation":[{"name":"2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Hall","sequence":"additional","affiliation":[{"name":"3PSR Group BV, Hoofddorp, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[{"name":"2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Makin","sequence":"additional","affiliation":[{"name":"4Otsuka Europe Development and Commercialisation Ltd, Wexham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[{"name":"2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"2025102312500229900_gfw240C1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C2","article-title":"2011 USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"US Renal Data System"},{"key":"2025102312500229900_gfw240C3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312500229900_gfw240C4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"2025102312500229900_gfw240C5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"2025102312500229900_gfw240C7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500229900_gfw240C8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C9","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2215\/CJN.00780110","article-title":"Renal function and healthcare costs in patients with polycystic kidney disease","volume":"5","author":"Lentine","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"(Suppl 4)","key":"2025102312500229900_gfw240C10","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500229900_gfw240C11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2025102312500229900_gfw240C12","article-title":"Autosomal Dominant Polycystic Kidney Disease Mutation Database: PKDB","author":"PKD Foundation"},{"key":"2025102312500229900_gfw240C13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500229900_gfw240C14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"2025102312500229900_gfw240C15","first-page":"1","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families","volume":"328","author":"Dalgaard","year":"1957","journal-title":"Acta Med Scand Suppl"},{"key":"2025102312500229900_gfw240C16","first-page":"25","article-title":"On the computation of morbid risk (disease expectancy)","volume":"5","author":"Nyholm","year":"1954","journal-title":"Acta Genet"},{"key":"2025102312500229900_gfw240C17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-0004.2010.01538.x","article-title":"Uptake of Huntington disease predictive testing in a complete population","volume":"80","author":"Morrison","year":"2011","journal-title":"Clin Genet"},{"key":"2025102312500229900_gfw240C18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ejhg.2008.142","article-title":"Problems assessing uptake of Huntington disease predictive testing and a proposed solution","volume":"17","author":"Tassicker","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"2025102312500229900_gfw240C19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500229900_gfw240C20","article-title":"ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2012","year":"2014"},{"key":"2025102312500229900_gfw240C21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.semnephrol.2010.06.002","article-title":"Diagnosis of autosomal-dominant polycystic kidney disease: an integrated approach","volume":"30","author":"Barua","year":"2010","journal-title":"Semin Nephrol"},{"key":"2025102312500229900_gfw240C22","first-page":"477","article-title":"Polycystic kidney disease re-evaluated: a population-based study","volume":"79","author":"Davies","year":"1991","journal-title":"Q J Med"},{"key":"2025102312500229900_gfw240C23","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1523-1755.2001.00758.x","article-title":"Prevalence of autosomal-dominant polycystic kidney disease in Alentejo, Portugal","volume":"59","author":"de Almeida","year":"2001","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C24","first-page":"249","article-title":"Mass-screening for early detection of renal disease: benefits and limitations of self-testing for proteinuria","volume":"22","author":"Heidland","year":"2009","journal-title":"J Nephrol"},{"key":"2025102312500229900_gfw240C25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2369-14-186","article-title":"Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry","volume":"14","author":"Martinez","year":"2013","journal-title":"BMC Nephrol"},{"key":"2025102312500229900_gfw240C26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2369-15-182","article-title":"Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study","volume":"15","author":"McGovern","year":"2014","journal-title":"BMC Nephrol"},{"key":"2025102312500229900_gfw240C27","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500229900_gfw240C28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","article-title":"Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study","volume":"57","author":"Patch","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2025102312500229900_gfw240C29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfu087","article-title":"Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure","volume":"29","author":"Shaw","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500229900_gfw240C30","first-page":"123","article-title":"Epidemiologic data, clinical and prognostic features of autosomal dominant polycystic kidney disease in a French region","volume":"17","author":"Simon","year":"1996","journal-title":"Nephrologie"},{"key":"2025102312500229900_gfw240C31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jramc-158-04-04","article-title":"Military nephrology: a review of cases 1985\u20132011","volume":"158","author":"World","year":"2012","journal-title":"J R Army Med Corps"},{"key":"2025102312500229900_gfw240C32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ndt\/gfs417","article-title":"Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease","volume":"28","author":"Helal","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500229900_gfw240C33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.amjhyper.2004.06.020","article-title":"Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population","volume":"17","author":"Kelleher","year":"2004","journal-title":"Am J Hypertens"},{"key":"2025102312500229900_gfw240C34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000354317","article-title":"A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease","volume":"38","author":"Kocyigit","year":"2013","journal-title":"Am J Nephrol"},{"key":"2025102312500229900_gfw240C35","first-page":"32, 35","article-title":"Making an earlier diagnosis of ADPKD: implications for the treatment of hypertension","volume":"20","author":"Perrone","year":"2006","journal-title":"Nephrol News Issues"},{"key":"2025102312500229900_gfw240C36","article-title":"ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2010","year":"2012"},{"key":"2025102312500229900_gfw240C37"},{"key":"2025102312500229900_gfw240C38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ndt\/gfp571","article-title":"The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration","volume":"25","author":"Hommel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"(Suppl 1)","key":"2025102312500229900_gfw240C39","doi-asserted-by":"crossref","first-page":"c247","DOI":"10.1159\/000342857","article-title":"Chapter 13 The linkage of incident renal replacement therapy patients in England (2002\u20132006) to hospital episodes and national mortality data: improved demography and hospitalisation data in patients undergoing renal replacement therapy","volume":"120","author":"Fotheringham","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"(Suppl 45)","key":"2025102312500229900_gfw240C40","first-page":"S7","article-title":"Reliability of administrative databases in epidemiological research: the example of end-stage renal disease requiring renal replacement therapy in patients with diabetes","volume":"26","author":"Nordio","year":"2009","journal-title":"G Ital Nefrol"},{"key":"2025102312500229900_gfw240C41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00467-002-1021-0","article-title":"Autosomal recessive polycystic kidney disease: outcomes from a single-center experience","volume":"18","author":"Capisonda","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"2025102312500229900_gfw240C42","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/j.1523-1755.2005.00246.x","article-title":"Autosomal-recessive polycystic kidney disease","volume":"67","author":"Parfrey","year":"2005","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s004670050281","article-title":"Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors","volume":"11","author":"Roy","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"2025102312500229900_gfw240C44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1651-2227.1996.tb14056.x","article-title":"Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft fur Padiatrische, Nephrologie","volume":"85","author":"Zerres","year":"1996","journal-title":"Acta Paediatr"},{"key":"2025102312500229900_gfw240C45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"2025102312500229900_gfw240C46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jech.48.6.596","article-title":"Cancer incidence: life table risk versus cumulative risk","volume":"48","author":"Schouten","year":"1994","journal-title":"J Epidemiol Community Health"},{"key":"2025102312500229900_gfw240C47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2288-10-97","article-title":"Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes","volume":"10","author":"Lim","year":"2010","journal-title":"BMC Med Res Methodol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/8\/1356\/24363800\/gfw240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/8\/1356\/24363800\/gfw240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:08Z","timestamp":1761238268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/8\/1356\/3059454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,20]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,6,20]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw240","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726438448.793520314","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726438448.793521823","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2016,6,20]]}}}